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Abstract
Background: The concept of individual burden, associated with disease, has been introduced recently to
determine the “disability” caused by the pathology in the broadest sense of the word (psychological, social,
economic, physical). Inherited ichthyosis belong to a large heterogeneous group of Mendelian Disorders of
Cornification. Skin symptoms have a major impact on patients’ Quality of Life but little is known about the burden
of the disease on the families of patients.
Objectives: To develop and validate a specific burden questionnaire for the families of patients affected by
ichthyosis.
Methods: Two steps were required. First, the creation of the questionnaire which followed a strict methodological
process involving a multidisciplinary team and families. Secondarily, the validation of the questionnaire, including
the assessment of its reliability, external validity, reproducibility and sensitivity, was carried out on a population of
patients affected by autosomal recessive congenital ichthyosis. A population of parents of patients affected by
ichthyosis was enrolled to answer the new questionnaire in association with the Short Form Q12 questionnaire
(SF-12) and a clinical severity score was filled for each patient.
Results: Ninety four families were interviewed to construct the verbatim in order to create the questionnaire and a
cognitive debriefing was realized. The concept of burden could be structured around five components: “economic”,
“daily life”, “familial and personal relationship”, “work”, and “psychological impact”. As a result, “Family Burden
Ichthyosis” (FBI) reproducible questionnaire of 25 items was created.
Forty two questionnaires were analyzable for psychometric validation. Reliability (Cronbach’s alpha coefficient = 0.89),
reflected the good homogeneity of the questionnaire. The correlation between mental dimensions of the SF-12 and
the FBI questionnaire was statistically significant which confirmed the external validity. The mean FBI score was 71.7 ±
18.8 and a significant difference in the FBI score was shown between two groups of severity underlining a good
sensitivity of the questionnaire.
Conclusions: The internal and external validity of the “FBI” questionnaire was confirmed and it is correlated to the
severity of ichtyosis. Ichthyoses, and other chronic pathologies, are difficult to assess by clinical or Quality of Life
aspects alone as their impact can be multidimensional. “FBI” takes them all into consideration in order to explain every
angle of the handicap generated.
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Background
Inherited ichthyoses form part of a large, clinically and
etiologically heterogeneous group of Mendelian Disorders
of Cornification and typically involve all or most of the
tegument [1]. All are characterized by chronic dryness,
hyperkeratosis and scaliness [1-3]. Both syndromic (with
extra-cutaneous manifestations), and non syndromic
forms of ichthyoses are described [1,4]. In non syndromic
inherited forms, the main types are the ichthyosis vulgaris
(MIM#146700) [5], the X-linked recessive ichthyosis
(MIM#308100) and Lamellar Ichthyosis (LI; prevalence
< 1:100000) which is one of the Autosomal Recessive
Congenital Ichthyosis (ARCI) [1,3,4]. In the recent new
classification, ARCI refers to Harlequin Ichthyosis and LI/
Congenital Ichtyosiform Erythroderma (CIE) phenotypic
spectrum of disorders [1]. LI is characterized by coarse
and brown or dark scaling [5]. Neonates with Harlequin
Ichthyosis go on to express a severe LI-like phenotype
which evovlves into generalized exfoliating erythrodermic
ichthyosis, whereas CIE is characterized by fine and white
scaling with varying degrees of erythema. In fact, ARCI
is characterized by visible signs and distressing
symptoms such as pruritus, fissures and cracks, limited
joints movements, reduced cutaneous sensitivity, water
loss, infectious risks, and sometimes severe ectropion
and/or eclabion. Global management is symptomatic
and often time-consuming. It includes baths, topical
emollient, topical keratolytic agents and sometimes
oral retinoid [3,4,6-9].
Several studies have focused on the negative impact of
ichthyosis on Quality of Life (QoL) mostly because of se-
vere erythema and hyperkeratoses [3,5,10-12]. However,
a specific questionnaire with a precise evaluation of the
impact of ichthyoses on the different aspects of daily life
has never been proposed.
Furthermore, for several years, the concept of “bur-
den” has taken an increasingly important place in the
medical field in evaluating the care of chronic diseases.
It was introduced by the World Health Organization
and was particularly useful for quantifying the health of
a population and determining the priorities of action in
the public health domain [13]. More recently, the con-
cept of individual disease burden has been introduced to
determine the “disability” in the broadest sense of the
word (psychological, social, economic, physical), and to
distinguish it from societal burden, which is primarily
concerned with its economic impact [14,15].
To assess the burden, data are collected using
questionnaires and there is a well defined methodology
to built and validate QoL questionnaires. However, the
burden questionnaires are still poorly developed. Two
previous published questionnaires for evaluating the
burden were established according to this rigorous
methodology of QoL questionnaires: the “Burden of
fibromyalgia” and the “Burden of chronic venous
disorders” [14,16].
The aim of this study was to create and validate a
French questionnaire to evaluate the burden on families
of patients affected by ichthyosis.
Patients and methods
We decided to develop a specific Family Burden Ichthyosis
questionnaire (“FBI”) according to the rigorous metho-
dology of construction of QoL questionnaires (Figure 1)
by two steps: creation of the questionnaire and validation
[17-19]. This methodology required a multidisciplinary
team involved in the care of the patients and their families.
Creation of the questionnaire
The study population: the “verbatim population”
Between July 2005 and December 2010, all the daily life
data concerning the ARCI patients followed in the “Centre
de Référence National des Maladies Génétiques à Expres-
sion Cutanée” (MAGEC) and their parents, and the
patient's and family's complaints, were systematically
collected by the social worker. These data were used for
the creation of a verbatim. The diagnosis of ARCI was
based on clinical, histological and when available, molecu-
lar results.
Construction process
This first step can be divided into three stages.
Stage 1: creation of the verbatim Data collection inclu-
ding the different complaints expressed by parents and by
affected children themselves during a one-on-one session
with the same social worker. For that, a French social
assessment has been used, inspired by a standardized
methodology (available on request).
Stage 2: analysis of the “verbatim” This stage allowed
the creation of a specific and relevant questionnaire. The
analysis has been realized by the social worker and by
the physicians. All questions have been gathered, and
submitted to a specialized team in the management of
ichthyosis at MAGEC. The aim was to simplify the ques-
tionnaire and to avoid redundancies. The questionnaire
was created in a question and answer format.
Stage 3 The cognitive debriefing was managed by the
Lionbridge Company. The aim was to verify the com-
prehension of the original French questionnaire in
terms of use of words and use of vocabulary to permit a
good understanding by everyone (i.e. different socio-
professional categories, duration of the disease; [20]). A
French native with a strong background in cognitive
interviewing techniques conducted each interview. The
questionnaire had to be discussed and modified if
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necessary. The samples had to be sufficiently represen-
tative of the population for which the instrument was
designed and the questionnaire was written in their
mother language.
Validation of the questionnaire
Study population: the “validation” population
The subjects fulfilling the following criteria were
included in the burden evaluation: parents of an
affected child (age < 18 years-old) suffering from ARCI
follow in MAGEC, fluent in French language, with oral
consent for participation. Inclusion started in May
2011 and was stopped when at least thirty subjects
were enrolled. This number was validated in previous
epidemiologic studies [21].
Validation process
Validation of the questionnaire included assessing its re-
liability, validity, reproducibility and sensitivity. The
questionnaire was anonymously administered to a group
of parents (mother or father). As it was anonymous, an
approval of an ethics committee was not considered as
necessary by our administrative instances.
The questionnaire distributed to the families consisted
of the new specific questionnaire to be validated, a com-
mon questionnaires: the Short-Form Q-12 (SF-12) and a
scale to evaluate the severity of ichthyosis [5]. The SF-12
is a common, validated QoL questionnaire that is simple
and short [22]. It measures the QoL based on the overall
health status. It has 2 dimensions: physical (PCS) and
mental (MCS), with scores between 0 and 100. The
Figure 1 Stages in questionnaire development.
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higher the score, the better the QoL. The SF12 is validated
in French. The severity of ichthyosis for each child, was
assessed with the published score of severity of MAGEC
[5]. It is based on the sum of the percentage of the scaly
surface, the percentage of the erythematous surface, the
intensity of pruritus and skin pain as measured through
visual analogue scale, and the severity of 10 symptoms of
ichthyosis (determined on a scale of 60).
The reliability or internal consistency was measured by
Cronbach’s α coefficient. This coefficient including 0 to
1 corresponds to a degree of homogeneity (internal
consistency). Coefficient scores > 0.7 usually indicate good
internal reliability or internal consistency. Furthermore, to
evaluate the external validity of the questionnaire and the
equability of the scale of our FBI questionnaire a compari-
son was performed with the SF-12 [23]. The cognitive
debriefing stage can replace with a relevant and efficient
method the test-retest step to study the reproducibility
(fewer patients involved, faster and more professional).
Finally, the sensitivity was assessed by comparing the FBI
score and the severity score.
The linguistic, cultural adaptation and validation have
subsequently made it possible for the “FBI” to be available
in English, based on the guidance of the International
Society for Pharmaco-economics and Outcomes
Research Principles of Good Practice for Translation
[24]. The final questionnaire was then tested in a sample
of native English UK-speaking subjects during an individ-
ual, cognitive debriefing interview to determine the
issues related to question and answer wording (ambigu-
ity, misunderstanding, acceptability, etc.). This cultural
adaptation and validation was performed by a specialized
institution (Lionbridge, Ireland).
Statistical analysis
The quantitative variables were compared using
Student's t-test or an ANOVA when there were more
than two groups. When the conditions necessary for the
application of these tests were not met, non-parametric
tests were used to compare the two groups (Mann
Whitney Wilcoxon). The qualitative variables were
compared using a Χ2 test. When the conditions neces-
sary for the application of this test were not met, the
Fisher exact test was preferred. A Cronbach’s α coeffi-
cient was measured to evaluate the reliability and a
Spearman’s correlation coefficient (r) was calculated to
assess the validity.
Results
Creation of the questionnaire
Construction process
The different steps showed that the concept of “burden”
could be structured around five dimensions: pain, daily
life, familial and personal relationship, work, and
psychological impact. The main topics and complaints
expressed by parents, found in the verbatim, were: “the
difficulties in finding someone to babysit their children”,
“the organization of holidays”, “the restrictions in terms
of leisure”, “the society’s perception”, and “the couple’s
problems”. The complaints least expressed by parents
were: “the management of siblings”, “the administrative
records to file”, “the itching at night”, and “the alimenta-
tion”. By using the verbatim, ninety six questions were
identified. However, it was decided that the expression
“the skin disease of our children” have to be included in
each item, to highlight the relation between skin disease
and each dimension.
The secondary analysis of the ninety six first questions
allowed a reduction to forty items. For example, three
questions about the general impact on the family QoL
were available: “the skin disease of our child makes our life
difficult”, “the skin disease of our child disrupts our family
life”, “the skin disease of our child disturbed our family
life”, finally one question was chosen: “the skin disease
of our child complicates our family life”. The item “I
feel guilty because of the skin disease of our child” was
modified to “I feel responsible for the skin disease of
our child” making it more relevant. At the same time,
we retained the different dimensions, while improving
their use.
The cognitive debriefing was realized and some
questions were changed to be more clear or easier to
understand by reforming sentences through changing
its order of words. For example, the item “During the
day, I think about my child’s skin disease continually”
was changed to “I spend the day thinking about my
child's skin disease”.
Finally, a multidimensional questionnaire: the “Family
Burden Ichthyosis questionnaire” was available in French
for parents which is simple to use and easy to under-
stand, consisting of forty items, and could be considered
as the final version to be validated. Each response was
scored from 0 to 3 (Table 1).
Validation of the questionnaire
Population of the study: the “burden’s evaluation”
population
The questionnaires were administered to the parents of
42 independent patients (17 girls, 25 boys mean age of
7.9 ± 4, 1; Table 2) suffering from LI or CIE from May to
August 2011. No one of these patients took part in the
verbatim group.
Validation process
Reproducibility
Reproducibility of the questionnaire was realized with
the cognitive debriefing method, and led us to modify
the structure of some questions.
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Reliability
The Cronbach α coefficient is 0.89, signifying a very
good internal consistency of the scale and a good homo-
geneity of the forty items.
Validity
The scale was compared to SF-12. The two SF-12
dimensions (mental and physical) were calculated. The
mean score for the SF-12 mental dimension was 28.7 ±
7.96 which expressed a significant impairment of the QoL.
The mean score for the physical dimension was 51.3 ± 6.9,
which didn’t express an impairment of QoL. The FBI
overall score, transformed into a scale of 100 points, was
calculated. The mean score was 71.71 ± 18.8, and the
scores of each dimension were also transformed to a 100-
point scale. The "daily’life" and "psychological impact"
dimensions were the most affected by the disease. The
correlations between FBI, severity score and SF-12 scores
are reported in Table 3. The correlation is statistically sig-
nificant for the mental dimensions of the SF-12 and the
FBI (α = -0.564, p = 0.002), but not for the physical dimen-
sion (α = -0.012, p = 0.46).
Sensitivity of FBI and severity scores
The mean severity score was 45.89 ± 22.86 (with a mini-
mum of 5 and a maximum of 94), and 17 subjects had a
score ≥ 50 (40.40%). The mean severity score for girls
was 43.37 ± 22.83 and for boys 48.54 ± 24.92. The differ-
ence between the two groups was not significant (p =
0.24). Furthermore, the severity score in children aged
under seven years was 42.68 ± 22.94 and, in children
aged from seven years or more, was 48.48 ± 23.71, the
different was also not significant (p = 0.20). The popula-
tion was homogeneous enough, it was not necessary to
do subgroups with age and sex. However, we realized
subgroups of severity; one group with a specific severity
score strictly under 50 (subgroup 1) and the other group
with a specific severity score greater than or equal to 50
(subgroup 2). In the subgroup 1 the overall FBI score
was 60.72 ± 19.16. In the subgroup 2 the overall FBI
Table 1 Below are a series of statements concerning your child’s skin disease, please answer as spontaneously as
possible
My child's skin disease has made us want to move. □definitely yes □maybe □definitely not □I don’t know
My child's skin disease has made me want to quit my job. □definitely yes □maybe □definitely not □I don’t know
My child's skin disease affects my sleep. □definitely yes □maybe □definitely not □I don’t know
My child's skin disease complicates our family life. □definitely yes □maybe □definitely not □I don’t know
I spend the day thinking about my child’s skin disease □definitely yes □maybe □definitely not □I don’t know
My child’s skin disease prevents us from going on vacation. □definitely yes □maybe □definitely not □I don’t know
My child needs more attention than other children because of his/her
skin disease.
□definitely yes □maybe □definitely not □I don’t know
Our child’s skin disease has forced us to rethink our plans for the future. □definitely yes □maybe □definitely not □I don’t know
Our child's skin disease causes us to neglect his/her brothers and sisters. □definitely yes □maybe □definitely not □I don’t know
My child’s skin disease prevents me from going to see my family. □definitely yes □maybe □definitely not □I don’t know
Because of my child’s skin disease, my family does not come to see us. □definitely yes □maybe □definitely not □I don’t know
Our child’s skin disease creates problems between me and my partner. □definitely yes □maybe □definitely not □I don’t know
I often feel frustrated after consultations related to our child’s skin disease. □definitely yes □maybe □definitely not □I don’t know
People's reactions to our child's skin disease are hard to accept. □definitely yes □maybe □definitely not □I don’t know
I feel guilty because of our child's skin disease. □definitely yes □maybe □definitely not □I don’t know
My child's skin disease has completely disrupted my life. □definitely yes □maybe □definitely not □I don’t know
I have not managed to accept our child's skin disease. □definitely yes □maybe □definitely not □I don’t know
I have a hard time getting used to the smell caused by our child's skin
disease.
□definitely yes □maybe □definitely not □I don’t know
Because of his/her skin disease, I have great difficulty finding someone to
babysit my child.
□definitely yes □maybe □definitely not □I don’t know
Because of his/her skin disease, my child has a lot of difficulties at school. □definitely yes □maybe □definitely not □I don’t know
Because of his/her skin disease, I fear for the future of my child. □definitely yes □maybe □definitely not □I don’t know
I'm growing tired of the daily care. □definitely yes □maybe □definitely not □I don’t know
I don’t feel well the day before I go to hospital. □definitely yes □maybe □definitely not □I don’t know
I don’t feel well the day after I go to hospital. □definitely yes □maybe □definitely not □I don’t know
The care I must provide to my child is extremely tiring. □definitely yes □maybe □definitely not □I don’t know
There are no rights or wrongs answers, only your answer. Thank you for your participation.
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score was 85.01 ± 7.23. The difference between the two
groups was statistically significant (p <0.0001). The
scores of the five dimensions (economic, daily life, famil-
ial and personal relationship, work, and psychological im-
pact) were statistically different between these two
subgroups. The p-values were 0,00001, 0,00002, 0,00004,
0,00109 and 0,00016 respectively. The more important the
severity was, the more altered the scores were (Table 3).
Discussion
Ichthyoses constitute a group of rare, chronic, and de-
bilitating diseases that are difficult to assess solely by
clinical or QoL elements, as their impact can be multidi-
mensional [3,5,10-12]. The DLQI scores place ichthyoses
among the skin disorders with the most harmful impact
on a patient’s QoL [5]. In children, the dermatologist
does not limit action to the skin care [6,9] but also aims
to prevent the sensory and psychomotor consequences
of these conditions [2,4,5]. Of note, it was also revealing
an increase of the resources utilization and cost (in the
United States) [10,25]. Thus, a global evaluation instru-
ment is needed (Figure 1). The provision of a specific
evaluation tool for assessing the burden of ichthyoses to
healthcare professionals is necessary for an objective and
constructive evaluation. Global burden is considered as
a “health breach” and allows the health authorities to
plan some pertinent health programs. Otherwise the
individual burden takes care of the patient himself (or its
family, its care giver) and describes the disability produced
by the disease in the broadest sense of the word (psycho-
logical, social, economic, physical). It allows to adapt the
management of patients in order to objectify and optimize
the improvement of their health [14,16]. The benefit
of our questionnaire is that it evaluates the family’s
feelings through the burden that conditions and takes into
account the QoL, integration within the community, life
organization and the level of medical resources consumed
(medical visits, treatment, etc.). It is also possible to assess
a drug or a non medicinal management with the modifica-
tion of the burden.
This questionnaire, the “FBI”, is the first powerful spe-
cific questionnaire compiled for ichthyosis in French
and was validated during the study (Table 1). It takes
each of the dimensions (pain, daily life, familial and per-
sonal relationships, work, and psychological impact) into
account to express the burden produced by this disease.
The validity of the FBI is confirmed by the significant
correlation with the score of the mental dimension of
the SF-12 (-0.564, p = 0.0002). Otherwise the score of
the physical dimension of the SF-12 didn’t suggest an
impairment of QoL and the correlation with the physical
dimension was not significant (Table 3). It could be
explained because the FBI is a burden questionnaire for
families and not for children, it was not surprising that
the physical dimension assessed in parents was not
altered. The relative young age of parents could be an-
other explanation. Other studies assessing the QoL of
parents of children affected by cutaneous diseases using
the SF-12 to compare with a more specific questionnaire
found the same results about the physical dimension of
SF-12 [26].
Even when the sample of patients is not very important,
we compared the FBI score with the severity score
assessed by the specific instrument create by MAGEC, in
order to assess the sensitivity of the FBI. The population
Table 2 Validation population
Lamellar ichthyosis CIE
Patients 30 12
Gender (F/M) 12/18 5/7
Age 8.3 (0–16.5) 7.6 (0–15)
Collodion Baby Syndrome 24 0
Oral Acitretin [1] 0 5
CIE = Congenital Ichtyosiform Erythroderma, F = Female, M =Male. [1] Topical
tazaroten and urea were not mentioned but have been used sporadically.
Table 3 Correlation between severity and FBI (dimension by dimension), SF-12 and FBI
“Familial and
personal
relationship”
“Daily life” “Economic” “Work” “Psychological
impact”
Severity
score
SF12
Physical
dimension
SF12
Mental
dimension
FBI 0.73283 −0.12121 −0.56438
<.0001 0.4623 0.0002
** **
SF12 Physical dimensions −0.27727 −0.14158 −0.14644 −0.03406 −0.05190 −0.08413
0.0875 0.3899 0.3737 0.8369 0.7537 0.6106
SF12 Mental dimensions −0.51752 −0.45132 −0.50177 −0.57600 −0.50151 −0.50815
0.0007 0.0039 0.0011 0.0001 0.0011 0.0010
** ** ** ** ** **
Severity Score 0.61204 0.67932 0.72605 0.54549 0.49912
<.0001 <0.0001 <.0001 0.0002 0.0008
** ** ** ** **
Cronbach α coefficient 0.82 0.71 0.84 0.72 0.64
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was organized into two subgroups according to the spe-
cific severity score being above or below fifty. The overall
score of the FBI proved to be highly and statistically
correlated with the severity score. The five FBI dimensions
were significantly correlated with the severity score. Fur-
thermore, it was shown that the more important the se-
verity was, the more altered the scores were. These results
underlined a good sensitivity of the new questionnaire.
This fact implies that globally, the FBI manages to show
the overall important impact of ichthyosis in all parents of
patients with this chronic and outwardly physical condi-
tion that should not be underestimated, even in the less
severe clinical forms.
These first results of FBI score, in a group of 42 ARCI
parents showed a high score and then, an important im-
pact on daily’s life of families (Tables 2 and 3).
Although the study is monocentric, it does not consti-
tute a limit of the study. Indeed, the studied population
is representative because MAGEC follows patients living
in France (and not only in Paris). On the other hand,
there is a selection’s bias given that the patients followed
in the center are affected by severe forms (severity score
greater or equal to fifty for 17 patients).
The FBI was also translated into English according to
the good practices based on cross cultural validation
(Table 1). The cross cultural validation will be realized in
German, Italian and Spanish. The next step in the process
of assessing burden of families with children affected by
ichthyosis will be to evaluate the possible changes in the
severity of the disease burden before and after treatment.
More specific aspects of other ichthyoses (i.e. Netherton
Syndrome and keratinopathic ichthyosis) need to be
discussed.
Conclusion
Our FBI questionnaire seemed to be a good tool for
evaluating the burden on families of patients with ich-
thyosis, and to be useful for improved multidisciplinary
monitoring of these patients and their family. With this
“Family Burden Ichthyosis” questionnaire, all aspects of
the multidimensional impact will be taken into consider-
ation in order to explain every angle of the handicap
generated contrary to a QoL questionnaire.
Additionally, the FBI questionnaire will help to valid-
ate different strategies to reduce the impact of these
acute and chronic affections on the experience of the
families of patients and on social integration.
Abbreviations
ARCI: Autosomal Recessive Congenital Ichthyosis; CIE: Congenital
Ichtyosiform Erythroderma; FBI: Family Burden Ichthyosis; LI: Lamellar
Ichthyosis; MAGEC: MAladie Génétique à Expression Cutanée; QoL: Quality of
Life; SF-12: Short-Form Q-12.
Competing interests
The study was conduct in association with Eau Thermale Avène.
Authors’ contributions
HD was involved in acquisition and interpretation of data; helped to draft
the manuscript and participated in revising it critically. SHR was involved in
acquisition of data and was involved in writing and revising the manuscript
for important intellectual content. CM and VS were involved in revising the
manuscript. CB contributed in establishing conception and design of study,
and was involved in writing and revising the manuscript for important
intellectual content. CT carried out basic conception and design of study,
analysis and interpretation of data, was involved in analysis of data, statistical
analysis and revising the manuscript. All authors read and approved the final
manuscript.
Author details
1Department of Dermatology, Necker-Enfants Malades Hospital, Centre de
Référence National pour les Maladies Génétiques à Expression Cutanée
(MAGEC), APHP, Paris, France. 2Université Paris V-Descartes, Paris, France. 3Eau
Thermale Avène, Lavaur, France. 4Public Health and Quality of Life, Pierre
Fabre, Boulogne, France.
Received: 22 November 2012 Accepted: 3 February 2013
Published: 15 February 2013
References
1. Oji V, Tadini G, Akiyama M, et al: Revised nomenclature and classification
of inherited ichthyoses: results of the First Ichthyosis Consensus
Conference in Sorèze 2009. J Am Acad Dermatol 2010, 63:607–641.
2. Di Giovanna JJ, Robinson-Bostom L: Ichthyosis: etiology, diagnosis, and
management. Am J Clin Dermatol 2003, 4:81–95.
3. Gånemo A, Sjöden PO, Johansson E, et al: Health-related quality of life
among patients with ichthyosis. Eur J Dermatol 2004, 14:61–66.
4. Oji V, Traupe H: Ichthyosis, clinical manifestations and practical treatment
options. Am J Clin Dermatol 2009, 10:351–364.
5. Bodemer C, Bourrat E, Mazereeuw-Hautier J, et al: Short- and medium-term
efficacy of specific hydrotherapy in inherited ichthyosis. Br J Dermatol
2011, 165:1087–1094.
6. Gånemo A, Virtanen M, Vahlquist A: Improved topical treatment of
lamellar ichthyosis: a double-blind study of four different cream
formulation. Br J Dermatol 1999, 141:1027–1032.
7. Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C, et al: Oral liazorazole vs. Acitretin
in the treatment of ichthyosis: a phase II/III multicentre, double-blind,
randomized, active-controlled study. Br J Dermatol 2007, 156:965–973.
8. Steijlen PM, Van Dooren-Greebe RJ, Van de Kerkhof PC: Acitretin in the
treatment of lamellar ichthyosis. Br J Dermatol 1994, 130:211–214.
9. Lacour M, Mehta-Nikhar B, Atherton DJ, et al: An appraisal of acitretin
therapy in children with inherited disorders of keratinisation.
Br J Dermatol 1996, 134:1023–1029.
10. Kamalpour L, Gammon B, Chen KH, et al: Resource utilization and quality
of life associated with congenital ichthyoses. Pediatr Dermatol 2011,
28:512–518.
11. Gånemo A, Lindholm C, Lindberg M, et al: Quality of life in adults with
congenital ichthyosis. J Adv Nurs 2003, 44:412–419.
12. Mazereeuw-Hautier J, Dreyfus I, Barbarot S, et al: Factors influencing quality
of life of inherited ichthyosis: a qualitative study in adult using focus
group. Br J Dermatol 2012, 166:646–648.
13. World Health Organization: About the Global Burden of Disease (GBD) project
[WWW document]; 2010. URL [http://www.who.int/healthinfo/
global_burden_disease/about/en/]
14. Guex JJ, Rahhali N, Taïeb C: The patient’s burden of chronic venous
disorders: construction of a questionnaire. Phlebology 2010, 25:280–285.
15. Meyer N, Paul C, Feneron D, et al: Psoriasis: an epidemiological evaluation
of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010,
24:1075–1082.
16. Serra E, Spaeth M, Carbonell J, et al: Development of the fibromyalgia
burden assessment: measuring the burden of fibromyalgia multifaceted.
Clin Exp Rheumatol 2010, 28(Suppl 63):S87–S93.
17. Seidenberg M, Haltiner A, Taylor MA, et al: Development and validation of
a multiple ability self-report questionnaire. J Clin Exp Neuropsychol 1994,
16:93–103.
18. Whalley D, McKenna SP, Dewar AL, et al: A new instrument for assessing
quality of life in atopic dermatitis: international development of the Quality of
Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004, 150:274–283.
Dufresne et al. Orphanet Journal of Rare Diseases 2013, 8:28 Page 7 of 8
http://www.ojrd.com/content/8/1/28
19. Smidt AC, Lai JS, Cella D, et al: Development and validation of Skindex-
Teen, a quality-of-life instrument for adolescents with skin disease. Arch
Dermatol 2010, 146:865–869.
20. Wild D, Grove A, Martin M, et al: ISPOR Task Force for Translation and
Cultural Adaptation. Principles of Good Practice for the Translation and
Cultural Adaptation Process for Patient-Reported Outcomes (PRO)
Measures: Report of the ISPOR Task Force for Translation and Cultural
Adaptation. Value Health 2005, 8:94–104.
21. Falissard B: Comprendre et utiliser les statistiques dans les sciences de la vie,
Abrégés. 2nd edition. Paris: Masson; 2005:68.
22. Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey:
construction of scales and preliminary tests of reliability and validity.
Med Care 1996, 34:220–233.
23. Collège des économistes de la santé: Guide méthodologique pour
l’évaluation économique des stratégies de santé; 2003:31–32 [http://www.ces-
asso.org/docs/Guide_Methodologique_CES_2003]
24. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson
P: ISPOR Task Force for Translation and Cultural Adaptation. Principles of
Good Practice for the Translation and Cultural Adaptation Process for
Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task
Force for Translation and Cultural Adaptation. Value Health 2005,
8:94–104.
25. Styperek AR, Rice ZP, Kamalpour L, et al: Annual direct and indirect health
costs of the congenital ichthyoses. Pediatr Dermatol 2010, 27:325–336.
26. Taieb C, Sibaud V, Merial-Kieny C: Impact of Avene hydrotherapy on the
quality of life of atopic and psoriatic patients. J Eur Acad Dermatol
Venereol 2011, 25(Suppl 1):24–29.
doi:10.1186/1750-1172-8-28
Cite this article as: Dufresne et al.: Family burden in inherited ichthyosis:
creation of a specific questionnaire. Orphanet Journal of Rare Diseases
2013 8:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Dufresne et al. Orphanet Journal of Rare Diseases 2013, 8:28 Page 8 of 8
http://www.ojrd.com/content/8/1/28
